Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, Status and Forecast 2020-2026

Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, Status and Forecast 2020-2026

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
1.4 Market Analysis by Type
1.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Asset Purchase
1.4.3 Collaborative R&D
1.4.4 Joint Venture
1.4.5 Licensing
1.4.6 Other
1.5 Market by Application
1.5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2020 VS 2026
1.5.2 Pharmaceutical Industry
1.5.3 Biotechnology
1.5.4 Medical Care
1.5.5 Education and Research
1.5.6 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2015-2026)
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Regions
2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Share by Regions (2015-2020)
2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter's Five Forces Analysis
2.3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Strategy
2.3.6 Primary Interviews with Key Cancer Monoclonal Antibody Partnering Terms and Agreements Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Market Size
3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2015-2020)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2015-2020)
3.1.3 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
3.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2019
3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
3.4 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
3.5 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2015-2020)
4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2021-2026)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application (2015-2026)
5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
6.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in North America (2019-2020)
6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
7.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Europe (2019-2020)
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
8 China
8.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
8.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in China (2019-2020)
8.3 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
8.4 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
9 Japan
9.1 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
9.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Japan (2019-2020)
9.3 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
9.4 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
10.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
10.4 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
11 India
11.1 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
11.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in India (2019-2020)
11.3 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
11.4 India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2015-2020)
12.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players in Central & South America (2019-2020)
12.3 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020)
12.4 Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 3SBio
13.1.1 3SBio Company Details
13.1.2 3SBio Business Overview and Its Total Revenue
13.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020))
13.1.5 3SBio Recent Development
13.2 4D Pharma
13.2.1 4D Pharma Company Details
13.2.2 4D Pharma Business Overview and Its Total Revenue
13.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.2.5 4D Pharma Recent Development
13.3 Abbvie
13.3.1 Abbvie Company Details
13.3.2 Abbvie Business Overview and Its Total Revenue
13.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.3.5 Abbvie Recent Development
13.4 Abzena
13.4.1 Abzena Company Details
13.4.2 Abzena Business Overview and Its Total Revenue
13.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.4.5 Abzena Recent Development
13.5 Adaptive Biotechnologies
13.5.1 Adaptive Biotechnologies Company Details
13.5.2 Adaptive Biotechnologies Business Overview and Its Total Revenue
13.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.5.5 Adaptive Biotechnologies Recent Development
13.6 Aeglea BioTherapeutics
13.6.1 Aeglea BioTherapeutics Company Details
13.6.2 Aeglea BioTherapeutics Business Overview and Its Total Revenue
13.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.6.5 Aeglea BioTherapeutics Recent Development
13.7 Agenus Bio
13.7.1 Agenus Bio Company Details
13.7.2 Agenus Bio Business Overview and Its Total Revenue
13.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.7.5 Agenus Bio Recent Development
13.8 Ascension
13.8.1 Ascension Company Details
13.8.2 Ascension Business Overview and Its Total Revenue
13.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.8.5 Ascension Recent Development
13.9 Ascentage Pharma
13.9.1 Ascentage Pharma Company Details
13.9.2 Ascentage Pharma Business Overview and Its Total Revenue
13.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.9.5 Ascentage Pharma Recent Development
13.10 Aslan Pharma
13.10.1 Aslan Pharma Company Details
13.10.2 Aslan Pharma Business Overview and Its Total Revenue
13.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
13.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
13.10.5 Aslan Pharma Recent Development
13.11 Telix Pharmaceuticals
10.11.1 Telix Pharmaceuticals Company Details
10.11.2 Telix Pharmaceuticals Business Overview and Its Total Revenue
10.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.11.5 Telix Pharmaceuticals Recent Development
13.12 Basilea Pharmaceutica
10.12.1 Basilea Pharmaceutica Company Details
10.12.2 Basilea Pharmaceutica Business Overview and Its Total Revenue
10.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.12.5 Basilea Pharmaceutica Recent Development
13.13 Bavarian Nordic
10.13.1 Bavarian Nordic Company Details
10.13.2 Bavarian Nordic Business Overview and Its Total Revenue
10.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.13.5 Bavarian Nordic Recent Development
13.14 Baxalta
10.14.1 Baxalta Company Details
10.14.2 Baxalta Business Overview and Its Total Revenue
10.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.14.5 Baxalta Recent Development
13.15 Bayer
10.15.1 Bayer Company Details
10.15.2 Bayer Business Overview and Its Total Revenue
10.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.15.5 Bayer Recent Development
13.16 Cantargia
10.16.1 Cantargia Company Details
10.16.2 Cantargia Business Overview and Its Total Revenue
10.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.16.5 Cantargia Recent Development
13.17 Apollomics
10.17.1 Apollomics Company Details
10.17.2 Apollomics Business Overview and Its Total Revenue
10.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.17.5 Apollomics Recent Development
13.18 Chiome Bioscience
10.18.1 Chiome Bioscience Company Details
10.18.2 Chiome Bioscience Business Overview and Its Total Revenue
10.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.18.5 Chiome Bioscience Recent Development
13.19 Clovis Oncology
10.19.1 Clovis Oncology Company Details
10.19.2 Clovis Oncology Business Overview and Its Total Revenue
10.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
10.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
10.19.5 Clovis Oncology Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Tables
Table 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Key Market Segments
Table 2. Key Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
Table 3. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Asset Purchase
Table 6. Key Players of Collaborative R&D
Table 7. Key Players of Joint Venture
Table 8. Key Players of Licensing
Table 9. Key Players of Other
Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2015-2020)
Table 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Growth Strategy
Table 20. Main Points Interviewed from Key Cancer Monoclonal Antibody Partnering Terms and Agreements Players
Table 21. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2015-2020) (Million US$)
Table 22. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players (2015-2020)
Table 23. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2019)
Table 24. Global Cancer Monoclonal Antibody Partnering Terms and Agreements by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
Table 27. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Type (2015-2020)
Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2021-2026)
Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Application (2015-2020)
Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 34. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Application (2021-2026)
Table 35. North America Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 37. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 38. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 39. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 40. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 41. Europe Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 43. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 45. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 47. China Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 48. China Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 49. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 50. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 51. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 52. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 53. Japan Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 55. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 57. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 61. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 63. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 65. India Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 66. India Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 67. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 68. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 69. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 70. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share (2019-2020)
Table 73. Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2015-2020)
Table 75. Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2015-2020)
Table 77. 3SBio Company Details
Table 78. 3SBio Business Overview
Table 79. 3SBio Product
Table 80. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 81. 3SBio Recent Development
Table 82. 4D Pharma Company Details
Table 83. 4D Pharma Business Overview
Table 84. 4D Pharma Product
Table 85. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 86. 4D Pharma Recent Development
Table 87. Abbvie Company Details
Table 88. Abbvie Business Overview
Table 89. Abbvie Product
Table 90. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 91. Abbvie Recent Development
Table 92. Abzena Company Details
Table 93. Abzena Business Overview
Table 94. Abzena Product
Table 95. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 96. Abzena Recent Development
Table 97. Adaptive Biotechnologies Company Details
Table 98. Adaptive Biotechnologies Business Overview
Table 99. Adaptive Biotechnologies Product
Table 100. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 101. Adaptive Biotechnologies Recent Development
Table 102. Aeglea BioTherapeutics Company Details
Table 103. Aeglea BioTherapeutics Business Overview
Table 104. Aeglea BioTherapeutics Product
Table 105. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 106. Aeglea BioTherapeutics Recent Development
Table 107. Agenus Bio Company Details
Table 108. Agenus Bio Business Overview
Table 109. Agenus Bio Product
Table 110. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 111. Agenus Bio Recent Development
Table 112. Ascension Business Overview
Table 113. Ascension Product
Table 114. Ascension Company Details
Table 115. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 116. Ascension Recent Development
Table 117. Ascentage Pharma Company Details
Table 118. Ascentage Pharma Business Overview
Table 119. Ascentage Pharma Product
Table 120. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 121. Ascentage Pharma Recent Development
Table 122. Aslan Pharma Company Details
Table 123. Aslan Pharma Business Overview
Table 124. Aslan Pharma Product
Table 125. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 126. Aslan Pharma Recent Development
Table 127. Telix Pharmaceuticals Company Details
Table 128. Telix Pharmaceuticals Business Overview
Table 129. Telix Pharmaceuticals Product
Table 130. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 131. Telix Pharmaceuticals Recent Development
Table 132. Basilea Pharmaceutica Company Details
Table 133. Basilea Pharmaceutica Business Overview
Table 134. Basilea Pharmaceutica Product
Table 135. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 136. Basilea Pharmaceutica Recent Development
Table 137. Bavarian Nordic Company Details
Table 138. Bavarian Nordic Business Overview
Table 139. Bavarian Nordic Product
Table 140. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 141. Bavarian Nordic Recent Development
Table 142. Baxalta Company Details
Table 143. Baxalta Business Overview
Table 144. Baxalta Product
Table 145. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 146. Baxalta Recent Development
Table 147. Bayer Company Details
Table 148. Bayer Business Overview
Table 149. Bayer Product
Table 150. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 151. Bayer Recent Development
Table 152. Cantargia Company Details
Table 153. Cantargia Business Overview
Table 154. Cantargia Product
Table 155. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 156. Cantargia Recent Development
Table 157. Apollomics Company Details
Table 158. Apollomics Business Overview
Table 159. Apollomics Product
Table 160. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 161. Apollomics Recent Development
Table 162. Chiome Bioscience Company Details
Table 163. Chiome Bioscience Business Overview
Table 164. Chiome Bioscience Product
Table 165. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 166. Chiome Bioscience Recent Development
Table 167. Clovis Oncology Company Details
Table 168. Clovis Oncology Business Overview
Table 169. Clovis Oncology Product
Table 170. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020) (Million US$)
Table 171. Clovis Oncology Recent Development
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2020 VS 2026
Figure 2. Asset Purchase Features
Figure 3. Collaborative R&D Features
Figure 4. Joint Venture Features
Figure 5. Licensing Features
Figure 6. Other Features
Figure 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2020 VS 2026
Figure 8. Pharmaceutical Industry Case Studies
Figure 9. Biotechnology Case Studies
Figure 10. Medical Care Case Studies
Figure 11. Education and Research Case Studies
Figure 12. Other Case Studies
Figure 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
Figure 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions: 2020 VS 2026
Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2019
Figure 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2019
Figure 21. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. 3SBio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 30. 4D Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 32. Abbvie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 34. Abzena Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 36. Adaptive Biotechnologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 38. Aeglea BioTherapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 40. Agenus Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 42. Ascension Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 44. Ascentage Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 46. Aslan Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)
Figure 48. Telix Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2015-2020)

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs